Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain by unknown
CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR
SELF TUMOR IMMUNOGLOBULIN EXPRESS
T CELL RECEPTOR S CHAIN
BY ANN WRIGHT, JEFFREY E. LEE,* MICHAEL P LINK,
STEPHEN D. SMITH, WILLIAM CARROLL,T RONALD LEVY,T
CAROL CLAYBERGER, AND ALAN M. KRENSKY
From the Departments of Pediatrics, 'Surgery, and TMedicine,
Stanford University School ofMedicine, Stanford, California 94305
One goal ofcancer research is toexploit the exquisite specificityofimmune recog-
nition to eliminate tumors in vivo. Although their role in immune surveillance of
tumor cellsremainsunclear, CTL are possible candidatesforadoptive immunotherapy.
The effectiveness ofthis therapy depends on CTL recognition ofspecific tumor an-
tigen. Ig on B cell lymphomas is an ideal tumor-specific antigen since it has a vari-
able region (idiotype) that istumor specific (1, 2). We report here that human CTL
specific for the idiotype on autologous B cell tumors could be selectively expanded
in vitro. The phenotype of these CTL is CD3+,CD4-,CD8- and they express the
S chain of the TCR. Such CTL could be grown in vitro for the treatment of B cell
lymphoma.
Materials and Methods
Cell Lines.
￿
Tumor cell lines were established as described (3) from the primary tumors
of three patients with Burkitt's lymphoma. The SUP-B8 cell line was derived from tumor
isolated from the bone marrow ofa 15-yr-old female with Burkitt's lymphoma with extensive
bone marrow involvement (B cell ALL). The patient achieved a complete remission after
treatment with chemotherapy but suffered an isolated central nervous system relapse. She
received an autologous bone marrow transplant, depleted of malignant cells with anti-BI mAb,
following preparation with total body irradiation and high dose cyclophosphamide. Recur-
rent B cell acute lymphoblastic leukemia was documented 5 wk after transplant, and 9 mo
after initial diagnosis. Peripheral blood was obtained from the patient at the time of leukemic
relapse. The SUP-B12 cell line was derived from tumor isolated from a 7-yr-old male with
Burkitt's lymphoma with extensive bone marrow involvement (B cell ALL). He was treated
with intensive chemotherapy and complete remission was documented 4 wk after the start
oftreatment. He received intensive maintenance chemotherapy, which was electively discon-
tinued 18 mo later. He remains in continuous complete remission. PBL were obtained from
this patient both during and after chemotherapy while in remission. The SUP-B17 cell line
was derived from the malignant ascites fluid from a 3 and 3/12-yr-old male who presented
with a primary Burkitt's lymphoma in the right lower quadrant ofthe abdomen. Bone marrow
and cerebrospinal fluid examinations were normal and he was designated stage III. Com-
plete remission was obtained with chemotherapy, which was electively discontinued after 15
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mo. This patient remains in continuous complete remission offof therapy. For all three pa-
tients, EBVtransformed B lymphocyte lineswere established from PBL (4). Tcell lines were
generatedby cocultureofpatient'sPBLwith an irradiated (10,000 rad) mixtureof autologous
tumor and EBVtransformed B lymphoblasts (5 :1). The CTL-A2 line was derived by cocul-
ture of the PBL from a normal donor (HLA-A3; B7, w38; DR6) with the irradiated B cell
line JY (HLA-A2; B7; DR4,6) (5, 6). Tumor and EBVtransformed cell lines were main-
tained in RPMI 1640 supplemented with 10% calf serum. T cell lines were maintained in
RPMI 1640 supplemented with 10% FCS and T cell growth factors (7) andwere stimulated
weekly with the irradiated mixturedesignated above. Cellswere cloned by limiting dilution (8).
5'Cr-release Assays.
￿
Assays were carried out for4h as previously described (9). Antibodies
were added at the beginning of the assay and were present throughout.
MonoclonalAntibodies.
￿
The followingmAbs specific fortheindicated moleculeswere used
for cell surface staining and/or inhibition of cytolysis: Leu-1/anti-CD1, OKT4/anti-CD4,
OKT8/anti-CD8; PA2.6/anti-HLA class I (10); OKT3/anti-CD3; TS1.16/anti-HLA class II
(11); TS1.18/anti-LFA-1 (CDw18) (9); WT31/antiTCRa/ß(12); TCR6I/antiTCR--y/S (13). The
antiidiotype, A, A, and K mAbs were prepared and characterized as described (14-16).
Results and Discussion
Antitumor CTL were derived by in vitro coculture of the PBL from three sepa-
rate patients with an irradiated mixture of theirautologous Burkitt'slymphoma tumor
cells plus an autologous B lymphoblastoid cell line derived from EBVtransformed
PBL. Cell lines generated under these conditions were stable for at least 6 mo in
continuous culture. Antitumor CTL could not be generated by culturing PBL from
two of these patients with only their autologous tumor cell lines (SUP-1112, SUP-
B17) without the EBVtransformed lines. This may reflect the lack of expression of
the lymphocyte function-associated antigen 1 (LFA-1) on the SUP-1112 and SUP-
B17 tumor cells (4). The SUP-118 cell line expresses normal levels of LEA-1 (4).
After the cells were in culture for 6 wk their specificity was ascertained with a
panel of 40 target cells (Fig. 1, with 16 representative lines). Cell lines were gener-
FIGURE.1.
￿
Specificity ofcytolysis by antitumorCTL. The
antitumor CTL from three patients were tested for cyto-
lytic activity in a standard
5'Cr-release assay (6)using an
E/T ratio of 1. These target cells represent the spectrum
of different HLA specificities, cell types, and Ig idiotypes
from the40 total target cells tested. HLAtypeswere deter-
mined by microcytotoxicity assays using both PBL and
tumorcell linesforeach patientat theHLAtyping labora-
tory, Stanford University Blood Center, Stanford, CA. SUP-
B12 is the autologous tumor line derived from patient 1,
SUP-118is the autologous tumorline derived from patient
2, andSUP-1117 is theautologous tumor line derived from
patient 3. The HLA types of the target cells used are: JY
(HLA-A2; B7; DR4,6), Daudi (HLA-A-; B-; DR6), IDF
(HLA-A26,w69; 1118,38; DR5),MST(HLA-A3; B7; DR2),
WT49 (HLA-A2; B17; DR3), LBF(HLA-A30; B12;DR7),
SB (HLA-A1,2; 1144,17; DR2,6), LB (HLA-Aw68; B40;
DR6), PALLY (HLA-A26,28.2; 1114,38; DR1,4), PGF
(HLA-A3; B7, DR2), LCL-158 (HLA-A32,w68; 1151,62;
DRI), SUP-118(HLA-A1,2;118,27;DR1,3), SUP-1112 (HLA-
A2,26; 117,35; DR4,6), SUP-1317 (HLA-A2,25; 1118,45;
DR2,4). No autologous EBVtransformed B cell line was
available for patient 2.ated from each patient on at least six separate occasions, and the specificity oflysis
by each line was similar to the results shown here. The CTL lines generated from
patients 1 and 3 lysed only their autologous tumor cell lines and not the autologous
EBV lines. The CTL line generated from patient 2 lysed not only the autologous
tumor cell line SUP-118 but also all targets expressing HLA-DR1 (Pally, LCL-158,
SUP-118 shown). Treatment ofthis heterogeneous CTL line with mAb to CD4 and
complement showed that only CD4+ CTL lysed the HLA-DR1+ targets whereas
CD4- CTL specifically lysed the autologous SUP-1117 tumor (data not shown).
To localize the epitopes ofthe tumor-specific antigens recognized by these CTL,
we tested mAb to idiotype, j,, and X or K for inhibition of cytolysis. The isotype
ofthe Igexpressed by the SUP-118 and SUP-1112 cell lines is U/ic; that oftheSUP-1317
cell line isA/X Ourspecificity controls were alloreactive CTL derived from normal
donors and specific for HLA-A2 (5, 6). In all three cases, mAbs to Ig specifically
inhibitedtumor directed cytolysis (Fig. 2). Lysis ofSUP-1112 cellsbythe autologous
CTL linewas specifically inhibited by anti-SUP-1112 idiotype and anti-,u. Similarly,
lysis ofSUP-118 cells by the autologous antitumor CTL line was inhibited by anti-
SUP-118 idiotype and anti-,u. Finally, lysis of SUP-1317 cells was inhibited by anti-X
and andidiotype, but not by anti-,u. In each case, lysis was inhibited only by the
mAb tothespecific tumor idiotype andnot by mAb toeither oftheother twotumor
idiotypes. Thus, Ig determinants canserveastarget antigens in anautologous system.
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FIGURE 2.
￿
mAbs to Ig inhibitcy-
tolysis by tumor-specific CTL. Ly-
sisoftumorcells by theautologous
antitumor CTL line or the HLA-
A2-specific CTLCTL-A2 wastest-
ed using an E/T ratio of 1:1 . The
targets were SUP-1112, SUP-118,
andSUP-1117 forpatients 1, 2, and
3, respectively. Similar inhibition
was observed at E/T ratios of 2:1
and 5:1 . These E/T ratios were
chosen becausethey fall on thelin-
earportion ofthelysiscurve. Puri-
fied antibodies wereaddedat afinal
concentration of 25 pg/mlto 5iCr-
labeled targetsfor20 minat room
temperature before theaddition of
CTL. Anti-ic chain was used for
SUP-118 and SUP-1312 and anti
chain was used for SUP-1117. Re-
sults shown are from one of five
similarexperiments. In experiments
notshown, mAbwere titrated from
50 pg/mldown to 1 jLg/ml. Inhibi-
tion was observed at all concentra-
tions andthe percent inhibition de-
creased proportionately with the
concentration of mAb.1560
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Sincecytotoxicity is tumor cell specific, thetarget determinants are presumably the
Ig idiotype.
To confirm that Ig was the target antigen and to establish the phenotype ofthese
tumor specific CTL, we cloned CTL by limiting dilution. Clones were obtained only
from patient 3. Clones that lysed the autologous tumor cell line SUP-1317 were ex-
panded. Four T cell clones lysed the autologous tumor cell line but not the autolo-
gous EBV B cell line or any of 40 othertarget cells tested, including SUP-138, SUP-
B12, and five other Burkitt's cell lines (data not shown). Lysis was inhibited by mAb
to A, but not by mAbs to u or the idiotype (Fig. 3). Thus, this particular CTL clone
may recognize an idiotypic determinant associated with the A light chain but dis-
tinct from the epitope recognized by the antiidiotypic mAb. The polyclonal CTL
line from which this CTL was cloned contained cells which could be inhibited by
mAb to A and idiotype (Fig. 2).
To identify other molecules involved in the lysis of the SUP-1317 tumor cells, we
tested mAb to various cell surface molecules for inhibition of cytolysis (Fig. 3). The
results for the heterogeneous CTL cultures and all four CTL clones were similar.
Lysis of SUP-1317 by clone 18 was inhibited only by the mAb to CD3 (OKT3) and
a mAb to the a subunit of LFA-1 (TSl/18); mAbs specific for CD4 (OKT4), CD8
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FIGURE 3.
￿
Effect ofmAbs spe-
cific forvarious CTLor target
cell molecules on cytolysis. Ly-
sis of SUP-1117 by the tumor-
specific clone 18 or the HLA-
A2-specific cell line CTL-A2
wastested with an E/T ratio of
1:1 . mAbs to Ig and to CDl
(Leu-1), CD3 (OKT3), LFA-1
(TSl/18), CD4 (OKT4), CD8
(OKT8),MHC classI(PA2.6),
andclassII(TSl/16)were added
at a final concentration of 25
Wg/ml to "Cr-labeled targets
for20 minat room temperature
before the addition of CTL.(OKT8), MHC class I (PA2 .6), and MHC class II (TSl/16) antigens had no inhibi-
tory effect .
In contrast, lysis ofboth SUP-1317 andJY cells by the HLA-A2-specificCTL line
CTL-A2 (5, 6) was inhibited by mAbs to HLA-class I, CD3, CD8, and LFA-1, as
hasbeen shownpreviously forCTLthatareHLA classIrestricted and expressCD3
and CD8 (5, 6, 9).
Since mAbs to CD4, CD8, or MHC molecules did not affect lysis by the tumor-
specific CTL clones, we examined the cell surface phenotype ofthe clones and the
heterogeneous CTL line fromwhich theywere derived (Fig. 4). All fourclones (rep-
resented byclone 18, panelA) and theparental anti-SUP-1317 T celllinewere strongly
positive for CD3 expression. Approximately two-thirds ofthe parental Tcell line
(panel B) expressed the CD8 molecule, but no 101314-expressing cells were detected.
None ofthe four clones expressed either CD4 or CD8 molecules. Since the lack of
expression of both CD4 and CD8 molecules has been associated with expression
ofthe TCRy/S (15-17), the molecular nature ofthe TCR on these cells was inves-
tigated with two mAbs to the TCR (Fig. 4 E-H). WT31, a mAb to a framework
determinant on the TCRa/(3-CD3 complex (12) reacted strongly with theJurkat
cell line (Fig. 4 H). TCR61 is a mAb to the TCR6 chain that was produced by im-
munization with the purified TCRy/6 complex from the leukemic cell line PEER
(13). Most CTL in the parental anti-SUP-1317 cellline were stained with the TCR61
mAb, while aminor population was positive for WT31 (Fig. 4 F). A representative
clone (clone 18) was positive for TCR61; no binding ofWT31 was detected (Fig.
4 E). Since, as far as is known, the TCR 6 chain is invariably expressed as part of
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FIGURE 4.
￿
FACS analysis ofTcell differentiation antigens andTCR structures on T cell lines.
Clone 18 (A and E), the parental anti-SUP-1317 T cell line (B and F), PEER (C and G), and
Jurkat (D and H) were stained with antibodies recognizing CD3 (Leu-4), CD4 (Leu-3), CD8
(Leu-2), the CD3-a/ß molecular complex (WT31), the S chain of the CD3-y/b complex (anti-
TCRSl), and an isotype matched negative control (2). Cells were treated sequentially with un-
conjugated mouse mAbs followed by FITC-conjugated goat antibodies to mouseIg. Cellswere
analyzed on a multiparameter FACS II.
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the TCR-7/6-CD3 complex (18), we assume that these cells also express the TCR
y chain.
Although TCR-6 genes are rearranged and expressed early in thymic ontogeny
(19-22), there are very few cells with TCRy/6 heterodimers detectablein the thymus
or periphery at birth. In human adults, only 3-10% of peripheral T cells express
a TCRy/b (23-25). Many IL-2-dependent T cell lines and clones that express TCR-y/b
exhibit cytotoxicity against a broad panel of tumor targets (16, 17, 27). Recognition
and cytotoxicity are neither restricted by nor directed against MHC antigens, so
that it is possible that T cells expressing TCRy/6 mediate MHC-unrestricted cyto-
toxicity. However, it is unclear whether such nonspecific cytotoxicity is a result of
in vitro culture or reflects the in vivo activity of these cells.
CTL lines with a similar specificity for autologous tumor targets were established
from these patients on >20 separate occasions over the past 2 yr. During this period,
patient 3 was on continuation chemotherapy and the percentage of CD3+,CD4-,
CD8- cells in his peripheral blood ranged from 15 to 50% (data not shown). We
cannot establish whether these CD4-,CD8-,y/b+ cells arose as a result of host
factors, such as malignancy or chemotherapy, or because ofthe stimulatory antigens
present on the autologous tumor. Nonetheless, our findings suggest a physiologic
role for T cells with TCR-y/b in MHC-unrestricted autologous tumor cell recogni-
tion and raise the intriguing possibility that some but not all (16, 28, 29) -y/b T cells
may be restricted by Ig determinants in much the same manner as a/,0 T cells are
restricted by MHC molecules.
Summary
CTL are thought to play a role in the elimination of transformed cells in vivo.
The effectiveness of such CTL is in part dependent on recognition oftumor specific
antigens. Among the best characterized tumor-specific antigens are the unique or
idiotypic determinants on the Ig of B cell lymphomas. Here we describe the genera-
tion and properties of human CTL specific for the idiotype on autologous B cell
tumors. These cells are CD3 +,CD4-,CD8- and express the b chain of the TCR.
Such cells may prove useful in tumor-specific adoptive therapy.
We thank L. Hopper for preparation of the manuscript and M. B. Brenner (Dana-Farber
Cancer Institute, Boston, MA) for kindly providing antiTCR61 mAb.
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